Diagnosis and Management of HYPERTROPHIC CARDIOMYPATHY

Diagnosis and Management of Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder characterized by unexplained left ventricular hypertrophy, myocyte disarray, and myocardial fibrosis. It affects approximately 1 in 500 individuals and displays marked clinical heterogeneity, ranging from asymptomatic disease to severe heart failure and sudden cardiac death. Accurate diagnosis and individualized management are essential to optimize outcomes and quality of life.

Pathophysiology and Clinical Spectrum

HCM is most often caused by autosomal dominant mutations in sarcomeric proteins, leading to abnormal myocardial architecture and impaired relaxation. The hypertrophy typically involves the interventricular septum but may be concentric, apical, or localized to other segments. Left ventricular outflow tract (LVOT) obstruction can occur at rest or with provocation due to systolic anterior motion of the mitral valve, contributing to symptoms and disease progression.

Clinically, patients may present with dyspnea, chest pain, palpitations, presyncope or syncope, and reduced exercise tolerance. However, many individuals remain asymptomatic for years, underscoring the importance of vigilant screening and follow-up.

Diagnostic Evaluation

1. Clinical Assessment
Diagnosis begins with a thorough history and physical examination. A family history of cardiomyopathy or sudden cardiac death is a critical clue. On auscultation, a systolic ejection murmur that increases with Valsalva maneuver suggests dynamic LVOT obstruction.

2. Electrocardiography (ECG)
ECG abnormalities are common and include left ventricular hypertrophy, deep Q waves, ST–T changes, and atrial arrhythmias. While not diagnostic alone, ECG findings support suspicion and prompt further evaluation.

3. Echocardiography
Transthoracic echocardiography is the cornerstone of diagnosis. It demonstrates increased wall thickness (≥15 mm in adults, or ≥13 mm with a positive family history), assesses LVOT gradients, mitral valve anatomy, and diastolic function. Provocative maneuvers (Valsalva, exercise) help identify latent obstruction.

4. Cardiac Magnetic Resonance (CMR)
CMR provides high-resolution assessment of myocardial morphology and fibrosis. Late gadolinium enhancement identifies myocardial scar, which has prognostic significance for arrhythmic risk and adverse outcomes.

5. Genetic Testing and Family Screening
Genetic testing can confirm sarcomeric mutations and guide family screening. First-degree relatives should undergo periodic clinical and imaging evaluation, even if asymptomatic.

Risk Stratification for Sudden Cardiac Death

A central aspect of HCM management is assessing the risk of sudden cardiac death (SCD). Major risk factors include prior cardiac arrest, sustained ventricular tachycardia, unexplained syncope, family history of SCD, massive hypertrophy, nonsustained ventricular tachycardia on monitoring, and extensive myocardial fibrosis on CMR. Risk models recommended by organizations such as the European Society of Cardiology and the American College of Cardiology help guide decisions regarding implantable cardioverter-defibrillator (ICD) therapy.

Medical Management

1. Symptom Control
First-line therapy aims to reduce symptoms and LVOT gradients. Beta-blockers are the mainstay, decreasing heart rate and improving diastolic filling. If symptoms persist, non-dihydropyridine calcium channel blockers (e.g., verapamil) are alternatives. Disopyramide may be added in obstructive HCM for its negative inotropic effect.

2. Heart Failure Management
In non-obstructive HCM with systolic dysfunction, standard heart failure therapies are used cautiously. Diuretics may relieve congestion but must be used judiciously to avoid worsening obstruction.

3. Atrial Fibrillation
Atrial fibrillation is common and poorly tolerated in HCM. Rhythm control is preferred when feasible, and lifelong anticoagulation is recommended regardless of CHA₂DS₂-VASc score due to high thromboembolic risk.

Septal Reduction Therapy

For patients with severe, drug-refractory symptoms and significant LVOT obstruction, septal reduction therapy is considered.

• Surgical Septal Myectomy: The gold standard, particularly in younger patients and those with complex anatomy. It provides durable gradient relief and symptom improvement.

• Alcohol Septal Ablation: A less invasive alternative for selected patients, inducing controlled septal infarction to reduce obstruction.

Choice of therapy should be individualized and performed in experienced centers.

Device Therapy

Implantable Cardioverter-Defibrillators (ICDs) are indicated for secondary prevention after cardiac arrest and for primary prevention in high-risk patients. ICDs significantly reduce mortality but require careful counseling regarding complications and long-term management.

Lifestyle and Counseling

Patients with HCM should receive individualized advice regarding physical activity. Competitive high-intensity sports are generally discouraged, while moderate recreational exercise is encouraged under supervision. Genetic counseling is essential for affected families to understand inheritance patterns and screening needs.

Emerging Therapies

Novel agents targeting sarcomere hypercontractility, such as myosin inhibitors, represent an important advance. These drugs have shown promise in reducing LVOT gradients and improving symptoms, potentially altering the disease course.

Conclusion

The diagnosis and management of hypertrophic cardiomyopathy require a comprehensive, multidisciplinary approach. Advances in imaging, genetics, risk stratification, and targeted therapies have transformed care, allowing most patients to achieve good functional status and longevity. Early diagnosis, individualized risk assessment, and tailored treatment remain the cornerstones of optimal HCM management.